A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms
Robyn M. Scherber(Blueprint Medicines (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Martin Goros(The University of Texas at San Antonio Health Science Center), Hans Carl Hasselbalch(Zealand University Hospital), Sarah Friis Christensen(Gundersen Health System), Holly L. Geyer(Mayo Clinic Hospital), Amylou C. Dueck(Mayo Clinic in Arizona), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center)
Cited by 0
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k